Global Patient Program
For many international patients, fertility treatment is shaped as much by logistics as by clinical decision-making. The “Two Visits to Dubai” model has been designed to simplify this journey reducing travel while maintaining continuity, precision, and safety.
The pathway is structured around two short visits. The first visit is for oocyte retrieval and embryo creation, typically completed within 24 hours. Following this, embryos are cultured to the blastocyst stage, with the option of PGTA using next-generation sequencing (NGS) to identify chromosomally normal embryos. These embryos are then vitrified, allowing time for recovery and planning without the pressure of an immediate transfer.
The second visit is for the frozen embryo transfer, again completed in a brief stay. By separating stimulation from transfer, the process allows for better endometrial preparation and contributes to a more controlled, patient-friendly experience.
Between these two visits, much of the treatment is coordinated remotely. Baseline investigations, hormonal monitoring, and ultrasound scans are carried out in the patient’s home country, in collaboration with local providers. Treatment protocols are individualized, with clear timelines and ongoing communication to ensure that each step is predictable and well supported.
Dubai offers a unique setting for such a model. It combines advanced medical infrastructure, international accessibility, and a well-regulated healthcare environment. Its geographic position allows convenient travel from Europe, Asia, and Africa, while its clinical standards support high-quality outcomes in assisted reproduction.
Equally important is the legal clarity within the UAE framework. Assisted reproductive technologies are governed by defined regulations, providing transparency around permitted treatments, embryo handling, and genetic testing. This structured environment enables both clinicians and patients to proceed with confidence, particularly in areas such as PGTA and family balancing, where legal boundaries vary significantly across countries.
The result is a program that is both clinically robust and logistically efficient—allowing patients to access advanced fertility care in a manner that is thoughtful, coordinated, and respectful of their time and circumstances.